Provided by Tiger Fintech (Singapore) Pte. Ltd.

IGC Pharma

0.2992
+0.00280.94%
Post-market: 0.2952-0.0040-1.34%19:28 EDT
Volume:76.19K
Turnover:22.59K
Market Cap:23.84M
PE:-2.47
High:0.2998
Open:0.2903
Low:0.2901
Close:0.2964
Loading ...

IGC Pharma names IGC-AD1 Phase 2 clinical trial ‘CALMA’

TIPRANKS
·
08 Jan

IGC Pharma Inc: Goal of Completing Enrollment and Calma Trial in Second Half of 2025

THOMSON REUTERS
·
08 Jan

IGC Pharma Inc: Ongoing Phase 2 Trial for Agitation in Alzheimer's Disease Has Been Officially Named Calma (Calming Agitation in Alzheimer's)

THOMSON REUTERS
·
08 Jan

Kebaya inscribed onto UNESCO intangible cultural heritage list

CNA
·
04 Dec 2024

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

ACCESSWIRE
·
02 Dec 2024

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

THOMSON REUTERS
·
25 Nov 2024

IGC Pharma Inc - No Serious Adverse Events or Deaths Reported in Trial

THOMSON REUTERS
·
25 Nov 2024

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Business Wire
·
25 Nov 2024

IGC Pharma reports Q2 EPS (2c) vs. (5c) last year

TIPRANKS
·
14 Nov 2024

IGC Pharma Q2 EPS $(0.02) Beats $(0.03) Estimate, Sales $412.00K Beat $300.00K Estimate

Benzinga
·
14 Nov 2024

IGC Pharma Inc: Qtrly Loss per Share $0.02

THOMSON REUTERS
·
14 Nov 2024

IGC Pharma Q2 Pretax Profit USD -1.717 Million

THOMSON REUTERS
·
14 Nov 2024

IGC Pharma Q2 Net Income USD -1.717 Million

THOMSON REUTERS
·
14 Nov 2024

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline

ACCESSWIRE
·
14 Nov 2024

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies

ACCESSWIRE
·
06 Nov 2024